Grandfield & Dodd’s Zimmer Biomet ZBH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.68M Sell
18,564
-3,503
-16% -$321K 0.09% 93
2025
Q4
$1.98M Sell
22,067
-12,165
-36% -$1.15M 0.11% 89
2025
Q3
$3.37M Sell
34,232
-4,138
-11% -$410K 0.19% 70
2025
Q2
$3.5M Sell
38,370
-7,500
-16% -$725K 0.2% 68
2025
Q1
$5.19M Sell
45,870
-2,075
-4% -$222K 0.32% 58
2024
Q4
$5.06M Sell
47,945
-11,072
-19% -$1.19M 0.31% 59
2024
Q3
$6.37M Sell
59,017
-13,237
-18% -$1.44M 0.38% 55
2024
Q2
$7.84M Sell
72,254
-23,628
-25% -$2.79M 0.5% 52
2024
Q1
$12.7M Sell
95,882
-23,684
-20% -$2.96M 0.8% 44
2023
Q4
$14.6M Sell
119,566
-7,250
-6% -$809K 1.01% 40
2023
Q3
$14.2M Sell
126,816
-528
-0.4% -$67.1K 1.05% 40
2023
Q2
$18.5M Sell
127,344
-176
-0.1% -$23.9K 1.3% 31
2023
Q1
$16.5M Sell
127,520
-245
-0.2% -$30.8K 1.15% 38
2022
Q4
$16.3M Sell
127,765
-162
-0.1% -$18.8K 1.19% 39
2022
Q3
$13.4M Sell
127,927
-1,397
-1% -$153K 1.09% 40
2022
Q2
$13.6M Buy
129,324
+1,890
+1% +$224K 1.07% 42
2022
Q1
$16.3M Sell
127,434
-4,014
-3% -$484K 1.11% 39
2021
Q4
$16.2M Buy
131,448
+57
+0% +$7.46K 1.04% 40
2021
Q3
$18.7M Sell
131,391
-230
-0.2% -$33.8K 1.3% 30
2021
Q2
$20.6M Buy
131,621
+174
+0.1% +$28.2K 1.42% 31
2021
Q1
$20.4M Sell
131,447
-1,077
-0.8% -$167K 1.53% 28
2020
Q4
$19.8M Sell
132,524
-381
-0.3% -$53.8K 1.56% 26
2020
Q3
$17.6M Buy
132,905
+1,519
+1% +$198K 1.58% 24
2020
Q2
$15.2M Sell
131,386
-960
-0.7% -$111K 1.47% 23
2020
Q1
$13M Buy
132,346
+402
+0.3% +$52.7K 1.53% 25
2019
Q4
$19.2M Buy
131,944
+695
+0.5% +$95.9K 1.75% 20
2019
Q3
$17.5M Buy
131,249
+188
+0.1% +$24.3K 1.72% 18
2019
Q2
$15M Buy
131,061
+692
+0.5% +$81K 1.48% 23
2019
Q1
$16.2M Buy
130,369
+309
+0.2% +$35.1K 1.68% 19
2018
Q4
$13.1M Sell
130,060
-958
-0.7% -$108K 1.55% 22
2018
Q3
$16.7M Buy
131,018
+3,126
+2% +$372K 1.72% 21
2018
Q2
$13.8M Buy
127,892
+3,124
+3% +$340K 1.52% 24
2018
Q1
$13.2M Buy
124,768
+4,952
+4% +$575K 1.47% 28
2017
Q4
$14M Buy
119,816
+9,662
+9% +$1.09M 1.5% 27
2017
Q3
$12.5M Buy
110,154
+4,748
+5% +$548K 1.41% 30
2017
Q2
$13.1M Buy
105,406
+512
+0.5% +$60.7K 1.55% 28
2017
Q1
$12.4M Buy
104,894
+2,342
+2% +$265K 1.54% 26
2016
Q4
$10.3M Buy
102,552
+10,190
+11% +$1.09M 1.33% 30
2016
Q3
$11.7M Buy
92,362
+1,448
+2% +$179K 1.53% 28
2016
Q2
$10.6M Buy
90,914
+1,597
+2% +$181K 1.49% 28
2016
Q1
$9.25M Buy
89,317
+1,205
+1% +$117K 1.34% 32
2015
Q4
$8.78M Buy
88,112
+6,180
+8% +$605K 1.33% 32
2015
Q3
$7.47M Buy
81,932
+269
+0.3% +$27K 1.25% 33
2015
Q2
$8.66M Buy
81,663
+116
+0.1% +$12.8K 1.32% 36
2015
Q1
$9.3M Buy
81,547
+1,900
+2% +$217K 1.42% 35
2014
Q4
$8.77M Buy
79,647
+31
+0% +$3.27K 1.36% 34
2014
Q3
$7.77M Buy
79,616
+36
+0% +$3.54K 1.22% 37
2014
Q2
$8.02M Sell
79,580
-1,267
-2% -$124K 1.21% 35
2014
Q1
$7.42M Buy
80,847
+4,182
+5% +$385K 1.17% 37
2013
Q4
$6.94M Buy
76,665
+5,650
+8% +$489K 1.13% 39
2013
Q3
$5.66M Buy
71,015
+29,113
+69% +$2.29M 1.01% 41
2013
Q2
$3.05M Buy
+41,902
New +$3.13M 0.58% 53

Other funds holding ZBH

Grandfield & Dodd's ZBH Position: Q1 2026 in Review

Grandfield & Dodd reduced its Zimmer Biomet (ZBH) stake by 16% in Q1 2026, selling an estimated $321K and leaving 18,564 shares worth $1.68M. The position accounts for 0.09% of the portfolio, ranked #93.

Grandfield & Dodd first reported a position in ZBH in Q2 2013 and has held it in 52 quarters since. The position peaked at $20.6M in Q2 2021. 912 funds tracked by Wall St. Rank hold ZBH as of Q1 2026.

  • Grandfield & Dodd held 18,564 shares of Zimmer Biomet worth $1.68M as of Q1 2026.
  • Grandfield & Dodd sold 3,503 Zimmer Biomet shares in Q1 2026, an estimated $321K.
  • Zimmer Biomet made up 0.09% of Grandfield & Dodd's portfolio in Q1 2026, its #93 holding.
  • Grandfield & Dodd first reported a position in Zimmer Biomet in Q2 2013 and has held it in 52 quarters since.
  • Grandfield & Dodd's Zimmer Biomet position peaked at $20.6M in Q2 2021.
  • 912 funds tracked by Wall St. Rank held Zimmer Biomet as of Q1 2026.

Based on Grandfield & Dodd's 13F filing for Q1 2026, filed 7 May 2026.